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Silica capsules enclosing P123 triblock copolymer
micelles for flurbiprofen storage and release†
Stef Kerkhofs,a Fadila Saı¨di,b Niels Vandervoort,a Guy Van den Mooter,c
Charlotte Martineau,b Francis Taulelleab and Johan A. Martens*a
Flurbiprofen was incorporated in 200–400 nm silica capsules filled with Pluronic P123 polyethylene
oxide–polypropylene oxide–polyethylene oxide triblock copolymer. The assembly process of the
capsules and the molecular organization of drug molecule, surfactant and silica were investigated using
SAXS, TGA, SEM, DLS, DSC, 13C single-pulse, CPMAS and 1H–1H two-dimensional NMR. Flurbiprofen
molecules are molecularly dispersed inside polypropylene cores of P123 surfactant micelles occluded in
a 20–30 nm thick silica shell. Flurbiprofen molecules in polypropylene cores of P123 micelles exhibit
high mobility and are easily released after introduction in simulated gastrointestinal fluid and the solubility
limit is reached within minutes. Release rates are favored at high pH due to acid dissociation of the
carboxylic acid group of the flurbiprofen molecule. The molecular environment of flurbiprofen in these
P123 filled silica capsules is different from ordered mesoporous silica materials synthesized using P123 as
sacrificial template having the drug molecules adsorbed on the silica surface of pore walls. These findings
uncover a new concept of storage and release of hydrophobic bioactive molecules.
Introduction
Pharmaceutical formulation of hydrophobic active compounds
with low aqueous solubility in gastrointestinal (GI) fluids is very
challenging, and the number of poorly soluble drug candidates
facing this problem is steadily increasing.1–4 Poor aqueous
solubility leads to low bioavailability of an oral drug due to
limited uptake along the GI tract.2 Formulation with silica,
and especially the ordered mesoporous silica (OMS) can offer
a solution. Drug molecules stored in OMS pore walls are
released upon contact with aqueous medium and generate a
pH-independent supersaturated solution favouring transe-
pithelial transport.2 OMS is a convenient carrier material
because of its chemical stability, inertness, biocompatibility
and ease of fuctionalization.5–7 OMS combines high surface
area and large pore volume with uniform pores that can be fine-
tuned in diameter from 2 to 50 nm. OMS is synthesized using
sacrificial supramolecular organic template, which is removed
through calcination. Drug molecules are loaded in the pores
via an impregnation or adsorption procedure involving the use
of an organic solvent.2,3,6,7 A more recent development is to
incorporate the active compound during the synthesis of the
OMS carrier material.3,5–9 In such synthesis process, the active
compound is solubilized in aqueous medium using an amphi-
philic surfactant, which together with the drug serves as the
supramolecular template for the mesoscopic ordering of the
silica. Some reported formulations are based on cetyltrimethyl-
ammonimum (CTAB) surfactant.3,6,9,10 The concept of active
compound release from OMS-embedded CTAB micelles has
been extended to nutraceuticals.9 The use of CTAB has some
drawbacks, however. It is considered toxic and has been reported
to present cytotoxicity comparable to some cancer drugs.7,11 The
use of non toxic templates such as anionic surfactants,3 alkyl
maltosides5 and triblock copolymer poloxamer7 surfactants have
been investigated. Generally, organic solvent is needed to dis-
solve the drugmolecules in the synthesis medium and to achieve
incorporation in the surfactant–silica composite.3,5
Here we report the synthesis of surfactant containing capsules
with high drug loading capacity. We discovered this material in an
attempt to prepare a flurbiprofen loaded COK-12, which is an
OMS which can be synthesized using Pluronic P123 triblock
copolymer surfactant at ambient temperature in citric acid–
citrate buffered solution.11,12 Flurbiprofen is a nonsteroidal
anti-inflammatory drug comparable to ibuprofen both in func-
tion as in chemical structure.13 It is administered in treatment
of arthritis, migraine and inflammation. Flurbiprofen is a
weakly acidic hydrophobic molecule, with a pKa of 4.2, melting
point of 117 1C and solubility of 8 mg l1 in demineralized
water.14–16 Owing to the acid dissociation of the carboxylic acid
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group the solubility is pH dependent, enabling pH control over
the release from its formulations.14 Capsules filled with P123
surfactant and flurbiprofen assembled spontaneously in the
synthesis mixture. The formation process and the molecular
organization of flurbiprofen, P123 surfactant and silica was
probed using DLS, SAXS, TGA, DSC and 1H and 13C solid-state
NMR, and in vitro release experiments.
Experimental section
Synthesis
Flurbiprofen–P123–silica capsule (FPS) was prepared by adapting
the synthesis procedure for COK-12 performed at room tempera-
ture and slightly acidic pH.11,12 Standard buffered P123 surfac-
tant solution was prepared by dissolving 4.0 g triblock copolymer
Pluronic P123 (BASF, Belgium), 3.684 g citric acid monohydrate
(Sigma Aldrich) and 2.540 g trisodium citrate dehydrate (Sigma
Aldrich) in 107.5 g demineralized water. 600 mg flurbiprofen
(Sigma Aldrich) was added to 100 ml of citrate buffered P123
surfactant solution. The solution was stirred until all flurbiprofen
was solubilized and an opaque micellar solution was obtained.
The initial pH of the citrate buffered, solution was 3.7. To this,
9.23 g sodium silicate solution (Merck, extra pure, 27% SiO2, 10%
NaOH), diluted in 26.64 g demineralized water was added while
stirring vigorously. A white suspension was obtained instanta-
neously, which was aged under quiescent conditions for 24 h.
Solid powder was recovered by filtration, washed with deminer-
alized water and dried at 50 1C. The pH was measured using a
Mettler Toledo, InlabsExpert Pro pH electrode. The pH of the
filtrate was 5.3. For the purpose of comparison, COK-12 was
synthesized using the same procedure in absence of flurbiprofen.
Materials characterization
Dynamic Light Scattering (DLS) of P123 micellar solution was
performed in polystyrene cuvettes on a 90Plus Particle Size
Analyzer (Brookhaven) equipped with 659 nm laser, under a
detection angle of 901. Fluctuations in the scattered light
intensity were correlated between 5 ms and 1 s. Correlation
functions were analyzed with Igor Pro 6.2, using the Clementine
package for modeling of decay kinetics based on the Maximum
Entropy method. Decay times were converted to hydrodynamic
diameters using the Stokes–Einstein equation, yielding intensity
weighted particle size distributions. The viscosity was determined
using a rolling ball viscometer (AMVn automated microvisco-
meter, Anton Paar).
Small Angle X-ray Scattering (SAXS) patterns of powder
samples were recorded at room temperature using a SAXSess
mc2 instrument (Anton Paar) with rotating powder cell, line-
collimated CuKa radiation and a 2D imaging plate detector in
combination with a temperature controlled RotorCell sample
stage. SAXS patterns were normalized to incident beam inten-
sity. Background subtraction and desmearing were performed
using SAXSquant software.
Nitrogen adsorption isotherms were recorded at 196.8 1C
on a Micromeritics Tristar 3000 apparatus (Micromeritics).
Samples were degassed at 100 1C for 12 h under nitrogen flow.
Specific surface area was estimated using the BET model in
the relative pressure range (P/P0) between 0.05 and 0.3. Pore
volumes were estimated using t-plot method.
Scanning Electron Microscopy (SEM) observations were
made with a Nova NanoSEM450 (FEI) operated at 1.5 kV.
Powder samples were dispersed on carbon tape and measured
without applying a conductive coating.
Thermogravimetric Analysis (TGA) was performed on a TA
Instruments TGA Q500 under oxidative atmosphere (O2 : N2
molar ratio of 9 : 1; flow rate of 100 ml min1). Samples were
heated to 850 1C at a heating rate of 5 1C min1.
Differential Scanning Calorimetry (DSC) was performed on a
TA instruments DSC Q2000. Samples were analyzed in crimped
aluminum pans, at temperatures from 20 1C to 130 1C using a
heating rate of 20 1C min1. Temperature measurement was
calibrated and validated using indium and n-octadecane standards
while enthalpy measurement was calibrated and validated using
indium standards.
Solid-state NMR spectra were recorded on an Avance Bruker 500
NMR spectrometer (static magnetic field of 11.7 T). The samples
were packed in 4 mm outer diameter zirconia rotors and spun at
10 kHz. 13C single pulsemeasurementswere performedusing a 5ms
901pulse, a short recycledelayof4 s recycle (to selectmobile species)
and 1H SPINAL-6417 decoupling. 1H - 13C cross-polarization
(CP-MAS) NMR spectra were recorded using a 3 ms 901 pulse for
1H, 50 kHz radio-frequency (RF) field on 13C, and 4ms contact time.
1H SPINAL-64 decoupling was applied during the acquisition
period. About 7000 transients were accumulated for each sample.
The 1H–1H 2D single-quantum single-quantum (SQ-SQ) NMR
spectra were recorded using the radio-frequency driven recoupling
(RFDR) sequence with recoupling times of 4.5 ms. The States
procedure18 was applied to obtain phase sensitive spectra. The 1H
and 13C chemical shift were referenced to tetramethylsilane (TMS)
at 0 ppm. The Dmfit software was used for the data analysis.19
Flurbiprofen release experiments
FPS powder was suspended in 0.1 M phosphate buffer (pH 6.8)
or 0.1 M HCl solution (pH 1.2). Typically, 288 mg FPS powder was
suspended in 240 ml dissolution medium. Flurbiprofen release
from the FPS suspension was performed under gentle agitation
using a rotary mixer at room temperature (25 1C). At specific
time intervals, with a first sample taken after 3 minutes, 1.5 ml
samples were collected and filtered through 0.45 mm PTFE
membrane before analysis. After 4 h release, the remaining
suspension was filtered to recover the solids for analysis.
To simulate release during the gastric-to-intestinal transi-
tion, 25 mg of flurbiprofen formulation was added to 20 ml HCl
(0.1 M) solution. After 1 h, 180 ml of 0.1 M phosphate buffer
solution was added. The suspension was sampled regularly to
monitor flurbiprofen release.
Flurbiprofen concentration in solution was determined
using HPLC-UV. The chromatographic system consisted of a
LaChroms L-7100 pump, a L-7200 autosampler, a UV-detector
model L-7420 set at 248 nm and a D-7000 interface (All from
Merck-Hitachi, Darmstadt, Germany). The column used was a
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Chromolith Performance RP-18e column (Merck-Hitachi,
Darmstadt, Germany) and the mobile phase consisted of phos-
phate buffer (0.01 M, pH 5.5) and HPLC grade acetonitrile in a
70 : 30 v/v ratio at a total flow rate of 1 ml min1. Flurbiprofen
UV signals were monitored and peaks were integrated using
D-7000 software. Standard curves were linear over the concen-
tration range of 1–300 mg l1.
Results and discussion
Synthesis of FPS
Pluronic P123 with formula (pEO)20–(pPO)70–(pEO)20 is a triblock
copolymer consisting of a central hydrophobic polypropylene oxide
(pPO) chain between two more hydrophilic polyethylene oxide
(pEO) chains. P123 unimers in aqueous solution self-assemble to
spherical micelles consisting of a hydrophobic core of pPO chains
and an fuzzy layer of pEO, which stabilizes the micelles sterically.20
In citric acid–citrate buffered aqueous solution, P123 triblock
copolymer self-assembled into spherical micelles measuring ca.
14 nm according to DLS (Fig. 1 and Fig. S1, ESI†), in agreement
with literature.12,21,22 Hydrophobic compounds added to micellar
P123 solution can be solubilized inside the hydrophobic pPO core
of the micelles, causing swelling.14,20,23–25 A typical example is the
addition of trimethyl benzene to provoke swelling of P123 micelles
serving as supramolecular sacrificial templates for wide pore OMS
materials synthesis.12,20,26–28 Pore diameters up to 30 nm have
been reached using this approach.26,27 Loading Pluronic P123 with
docetaxel (DTX), an antineoplastic anticancer drug, led to DTX
swollen micelles. Spherically shaped micelles as large as 84 nm
have been observed.29 Flurbiprofen loading into P123 micelles was
performed at pH 3.7 in order to prevent flurbiprofen from acid–
base dissociation and to maximize flurbiprofen uptake in the
micelles.14,23 Flurbiprofen addition to P123 micelle solution led
to a large increase of micelle size to ca. 180 nm (Fig. 1). Drug-to-
Pluronic ratio was high (ca. 1 : 6 w/w), a considerable amount of
flurbiprofen had to be incorporated inside the Pluronic micelles.
The here observed micellar size of 180 nm could be the result of
coalescence in addition to swelling.
Addition of sodium silicate to the buffered P123 solution
containing flurbiprofen led to rapid precipitation of a white
powder referred to as FPS (Flurbiprofen–P123–silica capsule).
Flurbiprofen was concentrated in the FPS material. The flurbi-
profen concentration in the filtrate was very low. Only about
1.5% of the initially added flurbiprofen was left in solution.
The flurbiprofen incorporation efficiency was 98.5%. The
flurbiprofen content of FPS determined through solubilization
in ethanol was 8.90 wt%.
Characterization of FPS
TGA analysis of FPS material in oxidizing atmosphere showed a
weight loss of roughly 60 wt% ascribed to P123 and flurbi-
profen (Fig. S2, ESI†). The presence of flurbiprofen and P123 in
FPS material was confirmed by 13C MAS NMR (Fig. 2a) showing
the signals of flurbiprofen and P123. Solubilization of flurbi-
profen inside Pluronic micelles was confirmed by 1H–1H 2D
Fig. 1 Intensity weighted size distribution of P123 micelles in citrate
buffered solution: (a) before flurbiprofen addition and (b) after flurbiprofen
addition, determined by DLS.
Fig. 2 (a) 13C CPMAS NMR spectrum of flurbiprofen, stars indicating the
position of spinning sidebands (i), 13C MAS NMR spectra of FPS, showing
both flurbiprofen and Pluronic P123 (ii) and of P123 in as-synthesized
COK-12 reference material (iii). (b) 2D 1H–1H SQ-SQ NMR correlation
spectrum of FPS. The circled signals are cross-peaks between flurbiprofen
protons and protons of pPO chains of P123.
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solid-state NMR (Fig. 2b). The 2D NMR revealed a close
proximity between the protons of the flurbiprofen molecules
and those of the pPO chains, being at a distance of only a few
Ångstro¨ms in order to enable the coupling.
In SEM (Fig. 3a and b) FPS appeared as aggregated spherical
particles with mean diameters of 200–400 nm. Closer inspection
of SEM images occasionally observed damaged spheres (Fig. 3c),
revealing the hollow nature and the formation of submicron
sized capsules with 20–30 nm shell thickness. The SAXS pattern
of FPS (Fig. 4a) essentially showed only one broad diffraction
peak revealing poor ordering. After removal of the P123 surfac-
tant and flurbiprofen through calcination at 550 1C, the material
did not show diffraction peaks.
The porosity of calcined FPS was investigated using nitrogen
adsorption (Fig. 5a). The nitrogen adsorption isotherm according
to IUPAC classification corresponds to type IV, with an H2 type
hysteresis loop. Such adsorption isotherm is characteristic
for macropores (diameters larger than 50 nm), which are filled
through capillary condensation only at very high relative pres-
sure. The strong hysteresis in the desorption isotherm and the
sudden release at P/P0 = 0.45 indicates the inner void can be
accessed through narrow, less than 2 nm wide openings. Accord-
ing to N2 adsorption, the silica shell indeed is microporous.
The micropore volume amounted to 0.164 cm3 g1. The formation
of micropores in silica materials synthesized using P123 surfactant
has been ascribed to pEO moieties embedded in the silica which
create micropores upon calcination. N2 adsorption behavior is
consistent with the presence of hollow capsules observed with
SEM (Fig. 3b).
These characterizations revealed FPS is different from
COK-12, while the only difference in the synthesis procedure
is the addition of flurbiprofen. FPS consists of 200–400 nm
spherical capsules, with 20–30 nm thick silica shell occluding
P123 and flurbiprofen. COK-12 is an OMS with hexagonal
platelet morphology, roughly 250 nm thick and 500 mm in
diameter.11,12 It has P6m hexagonal symmetry (Fig. 4c) by the
presence of hexagonal arrays of ca. 5 nm wide parallel channels.
In N2 adsorption these channels are responsible for an hysteresis
loop with steep parallel branches (Fig. 5b) characteristic of
capillary condensation in open ended cylindrical mesopores.11,12
The formation mechanism of COK-12 is known in detail. It
proceeds via coalescence of individual silica-coated spherical
Fig. 3 Low magnification SEM image of FPS material (a). Higher magni-
fications show details of intact (b) and damaged capsules (c).
Fig. 4 Powder SAXS patterns of as-synthesized and calcined materials: (a)
FPS; (b) calcined FPS; (c) calcined COK-12. Curves were shifted vertically
for clarity.
Fig. 5 Nitrogen sorption isotherm of FPS (a) and orderedmesoporous silica,
COK-12 (b) calcined at 550 1C. Isotherm (a) is characteristic for a material
with pores larger than 50 nm. The strong hysteresis at partial pressure P/P0 =
0.45 is indicative for narrow openings to these macropores. Isotherm (b)
displays ordered cylindrical mesopores of approximately 5 nm.
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micelles to form cylinders, which assemble in hexagonal arrays.12
Addition of flurbiprofen to the synthesis mixture causes strong
swelling of the spherical micelles from ca. 14 nm to 180 nm
(Fig. 1). Silica is precipitated on the surface of these extra-large
micelles upon addition of sodium silicate solution. The FPS
material corresponds to an orderless packing of silica coated
swollen micelles spheres occluding flurbiprofen-bearing P123
micelles according to SAXS (Fig. 4). The nitrogen adsorption
isotherm (Fig. 5) is in agreement with formation of large voids
with microporous windows. Calcination causes local damage and
formation of holes in the silica skin of the particles through
which the gaseous degradation products from P123 and flurbi-
profen can be evacuated.
Location and physical state of flurbiprofen in FPS
In DSC analysis, crystalline flurbiprofen displays a melting
peak at 115.6 1C (Fig. 6). The thermogram of FPS did not show
any signal related to melting of crystalline flurbiprofen, sug-
gesting flurbiprofen was molecularly dispersed or present in
amorphous state.
To further distinguish between crystalline, amorphous and
dispersed state, 13C single-pulse and 1H - 13C CPMAS NMR
spectra of FPS were recorded (Fig. 7). CPMAS transfer relies on
1H–13C dipolar interaction, which is averaged out to zero for
mobile moieties. On the contrary, in single pulse experiments
with short relaxation delay, only the mobile species are
detected. Crystalline species have a much longer longitudinal
relaxation time T1 values, and are not visible on the spectrum.
Therefore, using the combination of these NMR techniques, it
was possible to unambiguously distinguish between flurbi-
profen within the P123 micelles (detected with single-pulse
spectra; Fig. 7a and c) and extraneous flurbiprofen crystallized
outside the micelles (detected with CPMAS NMR; Fig. 7b and
d), without special sample manipulation. Quantitative analysis
of the 13C single-pulse NMR spectra is done by integrating the
13C resonances (e.g., that at 175 ppm, which corresponds to the
CQO from the flurbiprofen in the inclusion and the two narrow
signals at 75–76 ppm which are the CH2–O of the pPO moieties,
and taking into account the 70 pPO motives in the P123 as
mentioned in the experimental section). These results indicate
that a maximum 1 : 17 ratio between flurbiprofen molecules
and PO units is observed, in agreement with the ratio yielded by
the molar synthesis composition (1 : 19). Only when an excess
amount of flurbiprofen was added during synthesis, corre-
sponding to 4 times the nominal amount, the presence of
crystalline flurbiprofen was detected using CPMAS.
In vitro release of flurbiprofen from FPS
Release of flurbiprofen from FPS was investigated in phosphate
buffer (0.1 M, pH 6.8). Under the experimental conditions release
of the entire dose corresponded to a flurbiprofen concentration
of 120 mg flurbiprofen l1. In phosphate buffer the solubility of
flurbiprofen is about 2800 mg l1 such that sink conditions were
established.14,15 Flurbiprofen release was fast and quantitative
(Fig. 9). In the phosphate medium at pH 6.8 the carboxylic acid
function of flurbiprofen molecule is deprotonated, which
increases solubility. The release of flurbiprofen from FPS was
confirmed by 1H and 13C solid-state NMR of recovered solid
material after 4 h. Signals of the flurbiprofen molecules were no
longer present and only P123 remained (Fig. 10). TGA analysis
revealed that about 40% of the Pluronic was released in the
dissolution medium in 4 h (see ESI,† Fig. S5).
13C NMR resonance frequencies of flurbiprofen in FPS were
different from the ones of crystalline flurbiprofen. A closer
analysis showed that only the carbon atoms close to the
carbonyl function (lines labeled a, d, j, k and l) significantly
shifted position (Fig. 8). The crystalline form of flurbiprofen is
made of dimers, linked together through hydrogen bonding
between two neighboring carboxyl groups.30,31 The modified
chemical shifts confirmed dimers of flurbiprofen no longer
existed once flurbiprofen was solubilized in the P123 micelles,
which further indicated that the flurbiprofen molecules are
well dispersed and isolated in the micelles.
In simulated gastric fluid (pH 1.2) flurbiprofen release was
much more limited (Fig. 9). The solubility limit of ca. 6 mg l1
Fig. 6 DSC thermograms of (a) crystalline flurbiprofen and (b) FPS. Results
are represented endotherm down.
Fig. 7 13C single-pulse MAS NMR spectra of FPS (a) and a material with
4 times higher flurbiprofen content (c). Only flurbiprofen solubilized within
micelles is detected. 13C CPMAS NMR spectrum of FPS (b) and material
with 4 times higher loading (d). This spectrum reveals the presence of
crystalline flurbiprofen.
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was reached within minutes. Only about 5% of the introduced
dose was released. The retention of the majority of the flurbi-
profen in the FPS was confirmed by 1H and 13C solid-state NMR
spectra of the FPS solids recovered after 4 h (Fig. 10, see ESI,†
Fig. S3 and S5). Interestingly, 2D 1H–1H NMR revealed flurbi-
profen remained solubilized in the pPO core of the P123
micelles (see ESI,† Fig. S4).
A final release experiment simulated the gastric-to-intestinal
transition by examining release in SGF, followed by release in the
phosphate buffered media (Fig. 11). In SGF, release was limited
to 5.6% or 6 mg l1. Transfer to the phosphate buffered medium
released more than 90% of flurbiprofen within 20 minutes.
The drug delivery principle of FPS capsules is different from
OMS materials. Surfactant present inside the material also can
influence the release behavior. In general, the fast burst release
of flurbiprofen closely resembles the release profile of other
poorly soluble, weak acidic drug molecules loaded into SBA-15
silica materials via incipient wetness loading procedures.13,33
Active compounds loaded into evacuated pores typically adsorb
on the silica surface mainly through hydrogen bonds with
silanol groups present on the surface and are released via
competitive adsorption of water. As water molecules enter the
pores, water preferentially interacts with the surface silanols,
displacing the drug molecules. These drug molecules desorb
from the surface and are released from inside the porous
structure.13 Classically loaded indomethacin and glibencla-
mide showed similar differences in release behavior between
SGF and simulated intestinal fluid.33 Discrepancies in the
release of these drug compounds in SGF were partially ascribed
to charge interactions between the silica surface and the active
compounds. Under acidic conditions, the molecules are not
ionized, while the silica surface has a net positive charge,
whereas at neutral pH and in simulated intestinal fluid both
the drug molecules and the silica surface carry negative charges.
Fig. 8 13C single-pulse MAS NMR and 13C CPMAS NMR spectrum of FPS.
The molecule of flurbiprofen, with labeled carbon atoms, is shown as inset.
Assignment is made based on previously reported first-principle calcula-
tions.32 Dash lines indicate the signals that shift depending on the physical
state of flurbiprofen.
Fig. 9 Release of flurbiprofen form FPS in (J) simulated gastric fluid
(0.1 M, pH 1.2) and (K) phosphate buffer (0.1 M, pH 6.8) at 120 mg
flurbiprofen l1 dosage. The dashed line represents solubility of flurbi-
profen in SFG solution (6 mg l1)
Fig. 10 13C single-pulse MAS NMR spectra of FPS initial sample, and of
the same sample after flurbiprofen release experiments at pH 1.2 and 6.8.
Fig. 11 Release of flurbiprofen from FPS, simulating the gastro-intestinal
tract. After 60 minutes, aliquots were transferred from a 0.1 M HCl to a
0.1 M phosphate buffered solution (pH 6.8). 100% corresponds to a
concentration of 106.6 mg l1 in SGF and 10.66 mg l1 in phosphate
buffer. The horizontal dashed line represents the equilibrium solubility of
flurbiprofen in SGF (6 mg l1).
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Charge repulsion will likely promote desorption and subse-
quently release, while under acidic conditions drug molecules
remain embedded in the porous silica structure.33 A similar
explanation for the release mechanism can be applied here and
is consolidated by the stabilization of flurbiprofen inside the
hydrophobic pPO core of the P123 template at low pH and release
from the surfactant micelles due to ionization at more neutral
pH. The non release in SGF and inability to wash out the
surfactant template thus reflects the inability of water to enter
the silica capsules and effectively displace the surfactant and the
drug molecules.
Conclusions
Flurbiprofen is incorporated in non-ionic, non-toxic triblock
copolymer which forms spherical micelles, keeping the hydro-
phobic drug compound inside the hydrophobic core of the
surfactant micelle. Addition of sodium silicate at neutral pH
and room temperature leads to spontaneous formation of
200–400 nm capsules filled with flurbiprofen loaded surfactant
assemblies. Flurbiprofen was loaded into a mesoporous struc-
ture without the need to first evacuate the pores, thereby
avoiding additional loading steps. Characterization with DCS,
13C and 2D 1H–1H NMR spectroscopy shows flurbiprofen is
molecularly dispersed in the hydrophobic core of the pPO
micelles.
Release of flurbiprofen from the carrier material was con-
trolled by pH. Under acidic conditions, release is restricted due
to low solubility in the medium as well as enhanced hydro-
phobic interactions between flurbiprofen and PO chains of the
triblock copolymer assembly. At pH 6.8, characteristic of intestinal
fluid, flurbiprofen is deprotonated thus becoming more hydro-
philic, releasing from the hydrophobic environment of the surfac-
tant core and the carrier material.
This easy synthesis routine to load flurbiprofen in an inorganic
carrier material, solubilized in the surfactant template can possi-
bly be extended to other hydrophobic molecules. Hydrophobic
drug molecules are solubilized inside the hydrophobic core of
Pluronic P123 and directly immobilized inside the pores of the
inorganic silica capsule during material formation. This new
synthesis approach, using the citrate silicate synthesis procedure,
does not require any organic solvents and can be performed
under physiological conditions of room temperature and neutral
pH, making this a suitable method for the incorporation of
sensitive hydrophobic molecules inside porous silica carriers.
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